Hence, this study provides insights into the use of the mitophagy regulator FUNDC1 as a prognostic marker in pan-cancer from an immuno-oncological perspective, which could benefit future mechanistic studies and aid in the development of immunotherapies. Here, FUNDC1 is linked to cancer.